Lexicon Pharmaceuticals, Inc. (LXRX) NASDAQ

0.47

+0.0066(+1.42%)

Updated at April 02 12:02PM

Currency In USD

Lexicon Pharmaceuticals, Inc.

Address

2445 Technology Forest Boulevard

The Woodlands, TX 77381

United States of America

Phone

281 863 3000

Sector

Healthcare

Industry

Biotechnology

Employees

103

First IPO Date

April 07, 2000

Key Executives

NameTitlePayYear Born
Dr. Michael S. Exton Ph.D.Chief Executive Officer & Director01970
Dr. Alan J. Main Ph.D.Executive Vice President of Innovation & Chemical Sciences576,9621954
Mr. Brian T. CrumSenior Vice President, General Counsel & Secretary596,4791973
Dr. Craig B. Granowitz M.D., Ph.D.Senior Vice President & Chief Medical Officer652,4831965
Ms. Kristen L. AlexanderVice President of Finance & Accounting01968
Ms. Carrie SiragusaVice President of Marketing0N/A
Ms. Lisa M. DeFrancescoSenior Vice President of Investor Relations & Corporate Communications01980
Ms. Desiree GendronVice President of Sales & Training0N/A
Mr. Dixon TerryVice President of Compliance0N/A
Mr. Scott M. CoianteSenior Vice President & Chief Financial Officer01967

Description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.